Meridian Bioscience said today that despite a 12 percent overall drop in first-quarter revenues, it is maintaining a positive outlook for fiscal year 2011 based in part on the gradual uptake of its Illumigene amplification-based C. difficile test and positive contributions from its recently acquired Bioline business.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.